Vol 14, No 1 (2011)
Research paper
Published online: 2011-07-12
Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism
Nucl. Med. Rev 2011;14(1):3-8.
Abstract
BACKGROUND: The aim of the present work was to investigate
the influence of lithium carbonate on the kinetics of radioiodine
in the thyroid gland, and the long-lasting effect of radioiodine
therapy pre-treated with lithium carbonate in patients with different
types of hyperthyreosis and low baseline 24-h thyroidal
radioactive iodine uptake (RAIU).
MATERIAL AND METHODS: The examinations were performed in two groups of patients: in a control group with RAIU > 30% and in patients with RAIU < 30%. All groups were comparable with regard to age, sex, duration and type of disease (Graves’ disease, autonomous node, multinodular goitre). The control group was treated (without lithium) according to described protocol. The second group was pre-treated with lithium carbonate in a dose of 1.0 g/day for 6 days before radioiodine and 3 days thereafter.
RESULTS: A significant increase in iodide uptake in the thyroid gland was observed during intake of lithium carbonate in 106 out of 128 patients. A decrease of T3, FT3, T4, and FT4 levels and no significant changes in concentration of TSH were observed as an effect of lithium carbonate treatment. Three years of follow-up show that the results of radioiodine therapy with short lasting lithium carbonate intake are better in the first year and are similar in the second and third years in comparison to the control group.
CONCLUSIONS: Lithium pre-treatment in hyperthyroid patients with low baseline uptake of radioiodine can increase iodine retention in the thyroid gland independently of the primary disease and permits the use of lower doses of radiation in the therapy.
Nuclear Med Rev 2011; 14, 1: 3–8
MATERIAL AND METHODS: The examinations were performed in two groups of patients: in a control group with RAIU > 30% and in patients with RAIU < 30%. All groups were comparable with regard to age, sex, duration and type of disease (Graves’ disease, autonomous node, multinodular goitre). The control group was treated (without lithium) according to described protocol. The second group was pre-treated with lithium carbonate in a dose of 1.0 g/day for 6 days before radioiodine and 3 days thereafter.
RESULTS: A significant increase in iodide uptake in the thyroid gland was observed during intake of lithium carbonate in 106 out of 128 patients. A decrease of T3, FT3, T4, and FT4 levels and no significant changes in concentration of TSH were observed as an effect of lithium carbonate treatment. Three years of follow-up show that the results of radioiodine therapy with short lasting lithium carbonate intake are better in the first year and are similar in the second and third years in comparison to the control group.
CONCLUSIONS: Lithium pre-treatment in hyperthyroid patients with low baseline uptake of radioiodine can increase iodine retention in the thyroid gland independently of the primary disease and permits the use of lower doses of radiation in the therapy.
Nuclear Med Rev 2011; 14, 1: 3–8
Keywords: lithium carbonate131-IodinehyperthyroidismGraves’ diseasemultinodular goitreautonomous tumour
